Pig kidney keeps 66-year-old man off dialysis for 9 months before human transplant in world's first
A 66-year-old man received a genetically modified pig kidney transplant that kept him off dialysis for 271 days, before he subsequently received a kidney from a deceased human donor
Researchers reported this as the first documented case of a pig kidney xenotransplant successfully serving as a "bridge" to a later human organ transplant, with findings published in a peer-reviewed medical journal
The new human kidney began functioning immediately, with no evidence that the earlier pig kidney had sensitised the patient's immune system against the subsequent transplant
The case was carried out at a US academic medical center as part of ongoing clinical evaluation of pig-to-human kidney xenotransplantation
Xenotransplantation and Genetic Modification of Donor Pigs
Xenotransplantation is the transplantation of living cells, tissues or organs from one species (here, pigs) into another (humans). Pigs are used because their organ size and physiology closely resemble humans, but their tissues carry molecules the human immune system recognises as foreign, triggering rapid rejection unless neutralised through genetic engineering.
Key Details
- The primary rejection trigger is the enzyme encoded by the GGTA1 gene, which produces "alpha-gal," a sugar molecule present on pig cells but absent in humans and other primates; humans have pre-formed antibodies against alpha-gal, causing hyperacute rejection
- CRISPR-Cas9 gene-editing technology (developed 2012; awarded the Nobel Prize in Chemistry in 2020) enables precise knockout of genes like GGTA1 and insertion of human immune-regulatory genes into the donor pig genome
- Donor pigs used in current clinical trials carry multiple gene edits — ranging from single-digit knockouts of xenoreactive antigen genes (GGTA1, CMAH, B4GALNT2) to more extensive edits (up to several dozen) that also inactivate porcine endogenous retroviruses (PERVs) to reduce cross-species infection risk
The 271-day survival of the pig kidney demonstrates that multi-gene-edited pig organs can now function long enough in a human recipient to serve a genuine clinical purpose — buying time before a human organ becomes available — rather than only being a short-term experimental proof of concept.
The "Bridge to Transplant" Concept in Organ Failure Management
A "bridge" therapy is any intervention used to sustain a patient's health while they wait for a definitive treatment — a concept already established in cardiology (e.g., ventricular assist devices as a "bridge to heart transplant"). Applying this framework to kidney xenotransplantation reframes pig organs not necessarily as permanent replacements, but as temporary physiological support during the organ-donor waiting period.
Key Details
- Dialysis is the standard bridge therapy for end-stage renal disease patients awaiting a kidney transplant; the pig kidney in this case functioned as an alternative to dialysis for 271 days
- Global and Indian kidney transplant demand vastly exceeds donor supply; India's organ donation and transplantation network is coordinated by NOTTO (National Organ and Tissue Transplant Organisation) under the Ministry of Health and Family Welfare
- The Transplantation of Human Organs Act, 1994 (amended 2011) governs organ donation and transplantation regulation in India, though it does not currently address xenotransplantation
If validated at scale, pig-kidney bridging could reduce dialysis dependence and mortality among patients on transplant waiting lists — a scenario relevant to India's own organ-shortage context, even though India's xenotransplant research capacity remains limited compared to the US.
History and Regulatory Pathway of Clinical Xenotransplantation
Clinical pig-to-human organ xenotransplantation is a recent development, moving from animal models to living human recipients only in the 2020s under special regulatory pathways, before formal clinical trials began.
Key Details
- The first genetically modified pig heart transplant into a living human was performed in January 2022 at the University of Maryland Medical Center (patient David Bennett; survived about two months) under an FDA "compassionate use" (expanded access) authorisation
- The first genetically modified pig kidney transplant into a living human was performed in March 2024 at Massachusetts General Hospital (patient Richard Slayman); the current case represents a similar pig-kidney xenotransplant that has now progressed further to a successful subsequent human-organ transplant
- The US FDA authorised the first formal clinical trials for gene-edited pig kidney transplants in humans in September 2025, moving the field from single compassionate-use cases to structured trials
This case sits within a fast-moving regulatory arc — from single "compassionate use" cases (2022 onward) to authorised clinical trials (2025) — that UPSC could test as an example of how emerging biotechnologies transition from experimental to regulated clinical use.
- Duration off dialysis with pig kidney: 271 days, in a 66-year-old patient
- Key xenoreactive gene targeted for knockout: GGTA1 (produces the alpha-gal antigen)
- First pig heart transplant in a living human: January 2022, University of Maryland (patient David Bennett)
- First pig kidney transplant in a living human: March 2024, Massachusetts General Hospital (patient Richard Slayman)
- US FDA cleared first formal clinical trials for gene-edited pig kidney transplants: September 2025
- Gene-editing tool enabling these modifications: CRISPR-Cas9 (2020 Nobel Prize in Chemistry)
- India's organ transplant regulatory framework: Transplantation of Human Organs Act, 1994 (amended 2011); coordinated by NOTTO